Skip to main content

Tecovirimat News

Tecovirimat No Aid for Time to Lesion Resolution With Mpox

FRIDAY, Dec. 20, 2024 – The antiviral drug tecovirimat does not reduce the time to lesion resolution or pain among adults with mild-to-moderate clade II mpox and a low risk for developing severe...

SIGA Receives Approval from the FDA for Intravenous (IV) Formulation of TPOXX (tecovirimat)

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) – SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced that the ...

FDA Approves TPOXX (tecovirimat) as the First Drug for the Treatment of Smallpox

July 13, 2018 – The U.S. Food and Drug Administration today approved TPOXX (tecovirimat), the first drug with an indication for treatment of smallpox. Though the World Health Organization declared...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Tecovirimat patient information at Drugs.com